Capricor Therapeutics announced the pricing of its underwritten offering of 4,412,000 shares of common stock at a public offering price of $17.00 per share. The gross proceeds from the offering are expected to be approximately $75M, before deducting underwriting discounts and commissions and estimated offering expenses payable by Capricor and assuming no exercise of the underwriters’ option. Piper Sandler & Co. and Oppenheimer & Co. are acting as the joint book-running managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Closing Bell Movers: Alcoa up 6%, Steel Dynamics up 3% after Q3 results
- Capricor Therapeutics announces common stock offering, no amount given
- Tesla lower after ‘underwhelming’ robotaxi launch event: Morning Buzz
- Capricor Therapeutics announces long-term data from HOPE-2 OLE study
- Capricor Therapeutics price target raised to $77 from $40 at H.C. Wainwright